<DOC>
	<DOCNO>NCT02257931</DOCNO>
	<brief_summary>A significant increase resistant bacteria emerge HSCT recipient . For example , 25 % - 42 % enterobacteriaceae produce extend spectrum beta-lactamase ; 8 - 72 % Pseudomonas aeruginosa resistant least one 25 - 62 % three antibiotic class , 13 % Gram-negative bacteria cause multidrug-resistant ( MDR ) strain ( Trecarichi JI 09 , Mikulska BBMT 09 , Oliveira BMT 07 , Caselli Haemat 10 , Gudiol , JAC 11 ) . These resistant bacteria may associate increased mortality limit treatment option ( Caselli Haemat 10 , Poutsiaka BMT 07 , DiazGranadoz JID 05 ) . To provide currently best empirical coverage control grow resistance , knowledge trend antibiotic susceptibility , well risk factor essential . For reason propose perform non-interventional prospective multicentre study EBMT centre .</brief_summary>
	<brief_title>Gram-negative Bacteremia HSCT Recipients</brief_title>
	<detailed_description>Primary objective : To determine incidence pattern antimicrobial resistance among Gram-negative bacteria isolate blood HSCT patient first 6 month transplantation . Secondary Objective ( ) : 2 ) determine whether currently administer empirical therapy appropriate ; 3 ) determine mortality associate resistant vs. sensitive Gram-negative bacteria Primary endpoint : The proportion resistant pathogen among gram-negative bacterial pathogen isolate blood HSCT recipient first 6 month post HSCT . 1 . Pathogens resistant either one following : ceftazidime cefepime piperacillin-tazobactam 2 . Pathogens carbapenem resistance ( include ertapenem ) 3 . MDR pathogens Secondary endpoint : 1 . The proportion resistant Gram-negative pathogen list primary end-point among Gram-negative bacterial pathogen isolate blood HSCT recipient first 6 month post HSCT : - Gram-negative pathogen resistant fluoroquinolones - Gram-negative pathogen resistant least one aminoglycosides - Gram-negative pathogen resistant colistin - Gram-negative pathogen ( Pseudomonas ) resistant tigecycline - Acinetobacter spp . resistant ampicillin-sulbactam - Acinetobacter spp . resistant tetracyclin minocycline - Stenotrophomonas maltophilia resistant trimethoprim-sulfamethoxazole - Stenotrophomonas maltophilia resistant minocycline 2 . The outcome infection cause resistant pathogen vs. sensitive , include mortality cause within 7 day within 30 day ; 3 . The appropriateness currently administer empirical antimicrobial therapy ; Inappropriate initial antimicrobial therapy define empirical antibiotic regimen , give first 48 hour follow obtain blood culture , include least one antibiotic active vitro infect microorganism . Research design : Data episodes Gram-negative bacteria blood stream infection collect prospectively initiation condition treatment end first 6 month HSCT ( death lose follow-up , occur early ) . Data patient develop Gram-negative infection report use special MED C form include data pathogen antimicrobial susceptibility pathogen , treatment outcome , presence certain risk factor , addition data present MED A form . Patient 's data age , gender , primary diagnosis status disease , presence co-morbidities , HSCT type , donor type , condition regimen ( myeloablative versus reduce intensity ) , GVHD prophylaxis outcome time report obtain MED A form . Study Population : Inclusion criterion : Allogeneic autologous HSCT recipient , age , indication . Exclusion criterion : Patients willing participate . Expected number patient : 3650 HSCT patient recruit followed order obtain data 365 Gram negative episode . Basis calculation : Clinical assumption ~30 % HSCT patient bacteremia , half due Gram negatives=10-15 % HSCT patient . Depending local epidemiology , 40 % resistant least one antibiotic mention primary endpoint . Mortality resistant GN bacteremia 30-50 % . Mortality sensitive bacteremia 5-20 % . Statistical issue - The actual sample size analysis number N* episodes Gram-negative bacteremia observe . These observed N≤N* patient . For simplicity , assume one patient ↔ one episode , i.e . N=N* . - The total number transplant participate center recruitment period order observe N patient ( least ) episode Gram-negative bacteremia indicate T. We assume N = 10 % T. - Notice thus scenarios `` conservative '' , could expect observe patient episodes 10 % , multiple episode per patient . - We consider several scenario compute minimum sample size necessary obtain estimation incidence resistance among Gram-negative bacteremia episode precision equal 0.05 ( preferably ) 0.1 , assume value 20 % 60 % incidence . ( Confidence level interval estimate always equal 95 % ) . Scenarios also consider secondary objective . All calculation do use NCSS-PASS 2000 software . T=365 transplant ( N=3650 patient ) minimum number transplant necessary able get 95 % CI= ( 0.35,0.45 ) actual incidence resistance equal 40 % . Data Collection &amp; Statistical Analysis Plan : Center registration form send EBMT center begin study . It assess willingness participate provide background information number transplant performed/year , names responsible person , method use laboratory , etc . All episode blood stream Gram-negative bacterial infection collect prospectively since initiation conditioning treatment 6 month transplantation . All episodes Gram-negative bacteremia include , include multiple episodes patient . For episode Gram-negative bacteremia , additional information include relevant microbiological data collect use MED C form . MED C form include data Gram- negative isolate . Note , time patient new positive blood culture Gram - negative bacteria , new MED C form fill . Repeated isolation pathogen , vitro susceptibility consider one isolate . We ask MED C form send within 3 month end episode . The baseline data patient develop blood stream Gram-negative bacterial infection study period report use MED A form , routinely fill patient center belong EBMT . We ask fill within 3 month end 6 month HSCT ( earlier patient cease ) . Resistance antibiotic study in-vitro sensitivity test perform local laboratory . The characteristic local laboratory , include essential data method use determine susceptibility isolate guideline use determine susceptibility report Centre Registration Form . The collaborator center responsible report laboratory . Statistical analysis The analysis data mostly descriptive . The incidence resistance compute percentage , denominator number episodes Gram-negative bacteremia , numerator number episode classify `` resistant '' . The relationship Resistance prognostic factor / characteristic investigate mostly univariate analysis , apply standard summary measure ( table , quantiles ) non-parametric test ( chi-squared Fisher Exact , Mann-Whitney Kruskal-Wallis ) - categorical continuous variable respectively . Possibly , multivariate analysis could also apply , use logistic regression ; random effect model GEE could use account dependence observation - nest patient center . The short-term mortality ( 7 30 day ) compute percentage - unless relevant proportion loss follow-up observe . All data collection perform IDWP data office ( Leiden ) accord EBMT guideline .</detailed_description>
	<criteria>Allogeneic autologous HSCT recipient , age , indication . Patients willing participate .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>infection</keyword>
	<keyword>bacteria</keyword>
	<keyword>gram-negative</keyword>
	<keyword>HSCT</keyword>
	<keyword>allogeneic</keyword>
	<keyword>autologous</keyword>
	<keyword>recipient , age , indication</keyword>
</DOC>